Your browser doesn't support javascript.
loading
Blood-Brain Barrier Dysfunction and Aß42/40 Ratio Dose-Dependent Modulation with the ApoE Genotype within the ATN Framework.
Toniolo, Sofia; Di Lorenzo, Francesco; Bernardini, Sergio; Mercuri, Nicola Biagio; Sancesario, Giulia Maria.
Afiliação
  • Toniolo S; Cognitive Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX1 3AZ, UK.
  • Di Lorenzo F; Department of Systems Medicine, University of Rome 'Tor Vergata', 00133 Rome, Italy.
  • Bernardini S; Department of Systems Medicine, University of Rome 'Tor Vergata', 00133 Rome, Italy.
  • Mercuri NB; Non-Invasive Brain Simulation Unit, IRCSS Santa Lucia Foundation, 00179 Rome, Italy.
  • Sancesario GM; Department of Systems Medicine, University of Rome 'Tor Vergata', 00133 Rome, Italy.
Int J Mol Sci ; 24(15)2023 Jul 29.
Article em En | MEDLINE | ID: mdl-37569528
The definition of Alzheimer's disease (AD) now considers the presence of the markers of amyloid (A), tau deposition (T), and neurodegeneration (N) essential for diagnosis. AD patients have been reported to have increased blood-brain barrier (BBB) dysfunction, but that has not been tested within the ATN framework so far. As the field is moving towards the use of blood-based biomarkers, the relationship between BBB disruption and AD-specific biomarkers requires considerable attention. Moreover, other factors have been previously implicated in modulating BBB permeability, including age, gender, and ApoE status. A total of 172 cognitively impaired individuals underwent cerebrospinal fluid (CSF) analysis for AD biomarkers, and data on BBB dysfunction, demographics, and ApoE status were collected. Our data showed that there was no difference in BBB dysfunction across different ATN subtypes, and that BBB damage was not correlated with cognitive impairment. However, patients with BBB disruption, if measured with a high Qalb, had low Aß40 levels. ApoE status did not affect BBB function but had a dose-dependent effect on the Aß42/40 ratio. These results might highlight the importance of understanding dynamic changes across the BBB in future studies in patients with AD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article